1. Home
  2. Companies
  3. 1AD
  4. Material Events

AdAlta (ASX:1AD) — Material Events

ASX:1AD · 25 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 21 articles Notable 4 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
21
AdAlta and SHcell Unite to Advance Breakthrough CAR-T Therapy Beyond ChinaHigh
AdAlta and SHcell launch global collaboration to develop novel CAR-T cancer therapy outside China
2 Jan 2026 ·Collaboration Agreement Announcement ·85
AdAlta Partner Secures Approval for CAR-T Therapy in China’s Boao Lecheng ZoneMedium
AdAlta partner approved to provide CAR-T therapy for advanced mesothelioma in China under special access scheme
2 Sept 2026 ·Regulatory Approval Announcement ·85
AdAlta’s EW-001 Shows Durable Survival and Response in Mesothelioma TrialMedium
AdAlta reports ongoing patient survival and promising response rates in EW-001 mesothelioma trial
10 Aug 2026 ·Clinical Trial Update ·85
AdAlta Raises A$2.5M to Advance CAR-T Therapy BZDS1901 with FDA and Manufacturing MilestonesMedium
AdAlta raises A$2.5M to advance CAR-T therapy BZDS1901 with FDA and manufacturing milestones
4 May 2026 ·Capital Raising ·85
AdAlta’s EW-001 CAR-T Therapy Marks Two-Year Cancer-Free Survival in Mesothelioma PatientMedium
AdAlta's EW-001 CAR-T Therapy Shows Durable Complete Responses in Advanced Mesothelioma
5 Aug 2026 ·Clinical Trial Update ·Unexpected ·85
AdAlta Launches Groundbreaking CAR-T Collaboration, Raises $2.8M to Fuel GrowthMedium
AdAlta launches 'East to West' CAR-T cancer therapy collaboration, raises $2.8M, strengthens balance sheet
30 Jan 2026 ·Quarterly Activities Report ·85
AdAlta Advances CAR-T Therapy with East-to-West Strategy and Australian Manufacturing TransferMedium
AdAlta launches East-to-West CAR-T strategy with promising mesothelioma therapy and Australian manufacturing transfer
30 Apr 2026 ·Quarterly Activities Report ·85
AdAlta Moves Manufacturing of CAR-T Therapy to Australia After Rare Tumour ClearanceMedium
AdAlta initiates Australian manufacturing of promising CAR-T therapy BZDS1901 for advanced mesothelioma
29 Apr 2026 ·Operational Update ·85
AdAlta Clears US$1M Milestone to Unlock BZDS1901 Data and Australian ManufacturingMedium
AdAlta completes milestone payment for BZDS1901 CAR-T, advancing manufacturing and FDA engagement
1 July 2026 ·Milestone Payment and Development Update ·85
AdAlta’s CAR-T Therapy Delivers Rare Tumour Disappearances in Mesothelioma TrialMedium
AdAlta's CAR-T Therapy BZDS1901 Shows Promising Tumor Shrinkage and Safety in Advanced Mesothelioma Trials
1 Apr 2026 ·Clinical Trial Update ·85
AdAlta and Partners Target Cell Therapy Scale-Up with Automated IRO PlatformMedium
AdAlta, Oribiotech, and Cell Therapies partner to deploy automated cell therapy manufacturing platform in Asia Pacific
21 Apr 2026 ·Partnership Announcement ·85
AdAlta Secures EW-001 CAR-T Rights and Advances Manufacturing with FDA Engagement in SightMedium
AdAlta secures EW-001 CAR-T rights, advances manufacturing and FDA engagement, raises A$2.5M, and boosts AI capabilities
29 July 2026 ·Quarterly Activities Report ·75
AdAlta Secures Canadian Patent, Cementing AD-214’s Global ProtectionMedium
AdAlta secures Canadian patent for AD-214, completing major market protection
20 Mar 2026 ·Patent Grant Announcement ·75
AdAlta Taps FDA Expertise to Fast-Track CAR-T Therapy for MesotheliomaMedium
AdAlta engages FDA advisors to advance CAR-T therapy BZDS1901 for mesothelioma
25 May 2026 ·Regulatory Engagement Announcement ·75
AdAlta Advances Cell Therapy with FDA Alignment and Key Milestone PaymentMedium
AdAlta advances AdCella strategy with FDA alignment, milestone payment, and RDTI refund
21 Jan 2026 ·ASX Announcement ·75
AdAlta Secures $1.1M Placement to Fuel CAR-T Therapy AmbitionsMedium
AdAlta raises up to A$1.1 million in private placement to advance cellular immunotherapy strategy
20 Oct 2025 ·Capital Raising ·75
AdAlta Advances CAR-T Collaboration and Boosts Capital Amid $2.44M Half-Year LossMedium
AdAlta advances CAR-T collaboration, raises capital, reports $2.44M half-year loss
20 Feb 2026 ·Half Year Report ·75
AdAlta Advances CAR-T Licensing, Raises $1.6M to Strengthen Balance SheetMedium
AdAlta advances cellular immunotherapy licensing, raises $1.6M, strengthens balance sheet
28 Oct 2025 ·Quarterly Activities Report ·75
AdAlta Secures A$1.2M to Propel Groundbreaking CAR-T Cancer TherapyMedium
AdAlta raises A$1.2M in placement to advance CAR-T cancer therapy and 'East to West' strategy
13 Jan 2026 ·Capital Raising ·75
AdAlta Accelerates CAR-T Therapy Development with Shanghai Cell Therapy GroupMedium
AdAlta's AdCella advances CAR-T therapy development with Shanghai Cell Therapy Group, accelerating manufacturing and regulatory strategy
27 Mar 2026 ·ASX Announcement ·75
AdAlta Advances Cellular Immunotherapy Pipeline, Secures First Asset and Raises A$5.3 MillionMedium
AdAlta advances cellular immunotherapy pipeline, secures first asset, raises A$5.3M, reports FY2026 loss
21 Aug 2026 ·Annual Report ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.